SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2014 / Cilt: 39 - Sayı: 4

[Use of monocyte chemoattractant protein-1 in monitoring of renal functions of patients with diabetic nephropathy and its value as a prognostic marker in assessing renal injury]

İdrar monosit kemoatraktan protein-1'in tip II diyabetik nefropatili hastaların renal fonksiyonlarının takibinde kullanımı ve renal hasarın değerlendirilmesinde prognostik belirteç olarak değeri

Nazlı CANER YANIK
Emel AHISKALI ERİM
Cihan COŞKUN
Ekrem ORBAY
Pages
430–434
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Correlation of urinary MCP-1 was positive with urine albumin (r=0.389; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the relationship between modified diet in renal disease (MDRD) glomerular filtration rate (GFR) and ratio of urinary monocyte chemoattractant protein-1 (MCP-1)/ creatinin (urinary MCP-1) and urine albumin/creatinine rates (urine albumin) in type 2 diabetic nephropaty patients who were in different stages and to assess the use of urinary MCP-1 as a prognostic indicator in monitoring renal functions of these patients and in renal injury.Methods: This cross-sectional study included 100 diabetic patients (48 females, 52 males).
📊
Key Findings & Data:Patients were randomized into 3 groups based on renal function determined by urine albumin.
💡
Conclusion & Impact:Correlation of urinary MCP-1 was positive with urine albumin (r=0.389; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the relationship between modified diet in renal disease (MDRD) glomerular filtration rate (GFR) and ratio of urinary monocyte chemoattractant protein-1 (MCP-1)/ creatinin (urinary MCP-1) and urine albumin/creatinine rates (urine albumin) in type 2 diabetic nephropaty patients who were in different stages and to assess the use of urinary MCP-1 as a prognostic indicator in monitoring renal functions of these patients and in renal injury.Methods: This cross-sectional study included 100 diabetic patients (48 females, 52 males). Patients were randomized into 3 groups based on renal function determined by urine albumin. Patients who had urine albumin 300 mg/g were defined as macroalbuminuric (MAA) (n=29). Three groups were measured and compared.Results: Inter-group assessment was performed by using "Oneway ANOVA" and "Kruskal- Wallis" tests and significant differences have been found between urinary MCP-1 in three groups. Urinary MCP-1 was found to be 156.02 pg/g (41.28-478.60) in NOA group; 174.99 pg/g (100.89647.18) in MIA group and 245.71 pg/g (96.78-724.59) in MAA group. Urinary MCP-1 levels increased by increasing of albuminuria and by deterioration of renal function. Correlation of urinary MCP-1 was positive with urine albumin (r=0.389; p

Özet

Amaç: Bu çalışmanın amacı, farklı evrelerdeki tip 2 diyabetik nefropatili hastaların idrar monosit kemoatraktan protein-1 (MCP-1)/kreatinin oranları (idrar MCP-1) ile idrar albümin/kreatinin oranları (idrar albümin) ve Modified Diet in Renal Disease (MDRD) GFR değerleri arasındaki ilişkiyi belirlemek ve bu hastaların renal fonksiyonlarının takibi ve renal hasarın ileri evrelerindeki prognostik değeri açısından idrar MCP-1'in kullanımını değerlendirmektir.Metod: Bu kesitsel çalışmaya, tip 2 diyabetli 100 hasta (48 kadın, 52 erkek) dahil edildi. Hastalar, idrar albümin ile tespit edilen renal fonksiyonlarına göre 3 gruba ayrıldı. İdrar albümin 300 mg/g olanlar ise makroalbüminürik (MAA) (n=29) olarak tanımlandı. Üç grubun değerleri ölçüldü ve karşılaştırıldı.Bulgular: Gruplar arası değerlendirmede "Oneway ANOVA" ve "Kruskal Wallis" testleri kullanıldı ve grupların idrar MCP-1 düzeyleri anlamlı farklılık gösterdi. NOA grup idrar MCP-1= 156.02 pg/g (41.28-478.60), MİA grup idrar MCP-1=174.99 pg/g (100.89-647.18), MAA grup idrar MCP-1= 245.71 pg/g (96.78-724.59). Renal fonksiyonlardaki bozulma ve albüminüri artışı ile uyumlu olarak idrar MCP-1 artmaktadır. İdrar MCP-1 ile idrar albümin arasında pozitif (r=0.389; p

🔖

Cite This Article

YANIK, N. C., ERİM, E. A., COŞKUN, C., ORBAY, E. (2022). [Use of monocyte chemoattractant protein-1 in monitoring of renal functions of patients with diabetic nephropathy and its value as a prognostic marker in assessing renal injury]. Türk Biyokimya Dergisi, Cilt: 39 - Sayı: 4, 430–434. https://ajindex.com/articles/621206

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ritz E. Advances in nephrology: successes and lessons learnt from diabetes mellitus. Nephrol Dial Transplant 2001; 16 Suppl 7:46- 50
  2. Ritz E, Tarng DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant 2001; 16 Suppl 5:11-8
  3. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65(1):116-28
  4. Furuta T, Saito T, Ootaka T, Soma J, Obara K, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21(5):480-5
  5. Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003; 63(1):83-95
  6. Park IS, Kiyomoto H, Barnes JL, Woodruff K, Abbout HE. Glomerular monocyte infiltration in early streptozotocin-induced diabetes is associated with increased expression of transforming growth factor and cellular fibronectin. J Am Soc Nephrol 1994; 5:971
  7. Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002; 25(10):1829- 34
  8. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, et al. Upregulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58(4):1492-9
  9. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003; 26(8):2421-5
  10. Han SY, So GA, Jee YH, Han KH, Kang YS, et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004; 82(6):568-76
  11. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294(4):697-701
  12. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123(10):754-62
  13. Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996; 27(5):640-6
  14. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney